US Patent

US11173209 — Compositions for drug administration

Method of Use · Assigned to Aegis Therapeutics LLC · Expires 2038-02-06 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions that include an alkyl glycoside and a therapeutic agent, such as Epipen, to increase the bioavailability of the agent.

USPTO Abstract

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

Drugs covered by this patent

Epipen (epinephrine) · Pfizer Inc.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3979`	—	Epipen
`U-3979`	—	Epipen

Patent Metadata

Patent number: US11173209
Jurisdiction: US
Classification: Method of Use
Expires: 2038-02-06
Drug substance claim: No
Drug product claim: No
Assignee: Aegis Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.